Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals

[1]  Y. Ye,et al.  The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis , 2020, PloS one.

[2]  R. Sterling,et al.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. , 2019, Gastroenterology.

[3]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[4]  T. Asselah,et al.  Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study , 2019, The Lancet.

[5]  A. Paradiso,et al.  Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer , 2019, International journal of biological sciences.

[6]  K. Kerr,et al.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. , 2018, Journal of hepatology.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  G. Giannelli,et al.  Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals , 2018, Hepatology.

[9]  D. Samuel,et al.  The impact of treatment of hepatitis C with DAAs on the occurrence of HCC , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[10]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[11]  G. Dore,et al.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.

[12]  R. D. de Knegt,et al.  Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. , 2017, Gastroenterology.

[13]  B. Carr,et al.  Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients , 2017, The International journal of biological markers.

[14]  Y. Hoshida,et al.  Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals , 2017, BMC Medicine.

[15]  A. Facciorusso,et al.  DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment , 2016, PloS one.

[16]  A. Walker,et al.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[17]  P. Malfertheiner,et al.  Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). , 2015, Clinical nutrition.

[18]  M. Zoli,et al.  Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. , 2014, Seminars in oncology.

[19]  H. Nagai,et al.  Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. , 2013, Anticancer research.

[20]  S. Friedman,et al.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. , 2013, Gastroenterology.

[21]  B. Carr,et al.  Thrombocytosis and Hepatocellular Carcinoma , 2013, Digestive Diseases and Sciences.

[22]  G. Michalopoulos,et al.  Growth factor pathways in development and progression of hepatocellular carcinoma. , 2012, Frontiers in bioscience.

[23]  D. Sahani,et al.  HCC and angiogenesis: possible targets and future directions , 2011, Nature Reviews Clinical Oncology.

[24]  H. Thomas,et al.  Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. , 2011, Journal of proteome research.

[25]  Mohamed Hassan,et al.  Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways , 2009, Hepatology.

[26]  R. Ray,et al.  Hepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling , 2008, Journal of Virology.

[27]  J. Filmus,et al.  Glypican-3 as a serum marker for hepatocellular carcinoma. , 2005, Cancer research.

[28]  R. Matz.  Low serum creatinine levels in severe hepatic disease. , 1989, Archives of internal medicine.

[29]  T. Takabatake,et al.  Low serum creatinine levels in severe hepatic disease. , 1988, Archives of internal medicine.

[30]  M. A. Awad,et al.  Vascular endothelial growth factor (VEGF) as a biochemical marker for the diagnosis of hepatocellular carcinoma (HCC) , 2020 .

[31]  J. Kao,et al.  Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[32]  M. Zoli,et al.  Association of abnormal plasma bilirubin with aggressive HCC phenotype , 2014 .

[33]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..